References
- Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016;34:1097–103.
- Solomon A, Weiss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992;140:629–37.
- Teng J, Turbat-Herrera EA, Herrera GA. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes. Kidney Int 2014;86:738–46.
- Ward JE, SooHoo P, Toraldo G, Jasuja R, Connors LH, O'Hara C, Seldin DC. Metabolic phenotype in an AL amyloidosis transgenic mouse model. Amyloid 2011;18:40–1.
- Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157:1239–46.